Clinical Trial Update: Study of Low-Density Lipoprotein Cholesterol (LDL-C) Reduction Using Evolocumab (AMG 145) in Japanese Patients With Advanced Cardiovascular Risk [Phase 3]

View source ↗

Summary

Phase 3 study in Japanese patients with advanced cardiovascular risk evaluated LDL-C lowering with evolocumab (AMG 145); results were posted in 2015.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Dyslipidemia
• Hyperlipidemia

Drugs mentioned

• Repatha (Evolocumab)

Snippet

Sponsor: Amgen | Conditions: Hyperlipidemia or Mixed Dyslipidemia at High Risk for Cardiovascular Events | Phase 3 | Status: COMPLETED | Results posted: 2015-12-23